CD274 and colorectal carcinoma: Current clinical trials have demonstrated that CRC patients harboring dMMR/MSI-H can benefit from immune checkpoint inhibitors (ICIs) including monoclonal antibodies targeting the programmed cell death receptor-1 (PD-1) and programmed cell death ligand-1 (PD-L1) (Suarez-Carmona and Halama, 2024; Zhu et al., 2023).